Regulatory T cells (Tregs) play an important role in controlling alloreactivity after solid organ transplantation, but they may also impair antiviral immunity. We hypothesized that the Treg frequency and the Treg phenotype are altered in hepatitis C virus (HCV)-infected recipients of liver transplantation (LT) with possible prognostic implications. Tregs from 141 individuals, including healthy individuals, LT recipients with or without persistent HCV infections, and nontransplant patients with chronic HCV, were studied. A comprehensive phenotypic analysis was performed with multicolor flow cytometry, which included standard Treg markers [CD4 1 , CD25 hi , CD127 
Liver transplantation (LT) is a well-established treatment option for end-stage liver diseases. Since it was first performed in 1963, 1 long-term clinical outcomes have improved significantly; however, no major additional steps forward have been achieved in the most recent decade. Chronic hepatitis C virus (HCV) is the leading cause of LT in the Western world.
2 HCV reinfection of the liver graft is universal. 3 The natural history of HCV after LT is accelerated with higher levels of viremia and more rapid progression to fibrosis and cirrhosis. 4 Graft hepatitis after LT for HCV is, therefore, a clinical challenge, and more in-depth knowledge of the underlying pathogenesis is needed, especially to differentiate between recurrent HCV and rejection of the organ.
Regulatory T cells (Tregs) play a key role in immune homeostasis and are of particular importance after transplantation. Tregs form a subtype of CD4
1 cells with a defined immunoregulatory phenotype and are involved in immune tolerance. 5 Tregs are defined as CD4 1 CD25 hi FoxP3 1 cells (where FoxP3 indicates forkhead box P3). In addition, CD127 has been shown to correlate negatively with FoxP3, [6] [7] [8] and thus Tregs can also be defined as CD4
1 CD25
hi CD127 -cells. CD127 has the advantage of being able to identify Tregs with surface staining.
Tregs have been proven to be important in regulating alloreactive immunity after solid organ transplantation in several studies. 9, 10 For example, Treg frequencies 1 year after kidney transplantation may be predictive of long-term graft survival. 11 Over time, Tregs tend to decline after transplantation, but their suppressive capacity is maintained or even enhanced against donor antigens.
12 Studies in kidney transplant recipients correlated increased FoxP3 expression in transplanted kidneys with acute rejection episodes, 13 but they described reduced Treg frequencies in peripheral blood during chronic rejection.
14 Similarly, Tregs after bone marrow transplantation have been related to acute and chronic graft-versus-host disease, 15, 16 with reduced Treg frequencies possibly being involved in the development of chronic graft-versus-host disease. [17] [18] [19] There are fewer data about the role of Tregs after LT. Some studies have reported elevated Treg frequencies in the blood of patients with tolerant grafts not requiring immunosuppressive medications. [20] [21] [22] Not only conventional Tregs but specifically CD45RA 1 Tregs with a naive phenotype have been shown to be elevated in tolerant patients after LT. 23 In contrast, decreased frequencies of circulating Tregs have been found during acute rejection episodes in LT patients, 24, 25 whereas Tregs seem to be enriched in livers with histological evidence of rejection after pediatric 26 and adult LT. 27 HCV infection has been shown to be associated with an altered Treg phenotype and function. The frequency of Tregs is elevated in patients with chronic HCV versus recovered and healthy controls, 28 and Tregs are able to suppress HCV-specific T cell responses. 29 In HCV infections after transplantation, Tregs have been suggested to play a role in the progression to fibrosis through the determination of the magnitude of the antiviral immune response. 30, 31 Nevertheless, previous studies of the role of Tregs in LT have had various limitations, such as rather small sample sizes, a lack of control groups, and limited phenotypic characterization beyond the standard CD4 
CD127
-Treg classification. The aim of this study was, therefore, to overcome past constraints and perform a comprehensive phenotypical characterization of Tregs in LT recipients with a particular focus on posttransplant HCV. Specifically, we aimed to determine whether specific Treg characteristics are associated with HCV infection and graft rejection. In-depth knowledge of Tregs is fundamental for understanding how Tregs can prevent graft rejection and for determining their role in graft hepatitis.
PATIENTS AND METHODS

Patient Cohort and Study Design
Overall, 141 individuals with available peripheral blood samples were studied; they included liver transplanted patients (LTx, n 5 83), nontransplant patients with chronic hepatitis C (HCV chr patients; n 5 24), and healthy controls (n 5 34).
All patients undergoing transplantation because of HCV-related liver disease (HCV LTx, n 5 35) had a graft reinfection, and none of them received antiviral therapy after transplantation until the time of our study. Patients undergoing LT because of hepatitis B virus (HBV) or alcoholic cirrhosis (non-HCV LTx patients; n 5 24) had no signs of recurrence of the initial underlying liver disease and were, therefore, used as controls within the transplant cohort for comparison with HCV LTx patients. The remaining patients (n 5 24) underwent transplantation because of various causes of irreversible liver dysfunction (primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, Wilson's disease, acute liver failure, cryptogenic cirrhosis, Budd-Chiari syndrome, polycystic liver disease, cystic fibrosis, and primary hepatocellular carcinoma). Patient populations are shown in Supporting Fig. 2 .
In all, 121 peripheral blood samples from LT patients were studied (repeat samples were available from 31 patients). Thirty-five samples were collected in the first 6 months after transplantation, 47 samples were collected 7 to 15 months after transplantation, and the rest (n 5 39) were collected from patients undergoing transplantation more than 16 months ago. In 87 cases, liver biopsy was performed on the day of the blood drawing; 49 were conducted per protocol, and the rest (n 5 38) were indication biopsies. Biopsy samples were evaluated with respect to rejection or graft HCV by 2 independent pathologists (J.S. and T.K.) according to the rejection activity index. 30 Standard immunosuppression for the transplant patients consisted of tacrolimus (48%) or cyclosporine A (49%). Sixty-one percent of the patients in all received steroids as part of their standard therapy (40% of HCV LT patients).
Two additional control groups, which consisted of patients with chronic HCV (n 5 24) and healthy volunteers (n 5 34), were studied. None of the HCV patients were receiving antiviral therapy at the time of the blood drawing.
Baseline characteristics of the LT patients are shown in Table 1 , and characteristics of the HCV patients are shown in Table 2 . The laboratory values at the time of the blood drawing are shown in Table 3 .
Ethics Statement
The study was approved by the ethics committee of Hannover Medical School in Hannover, Germany (record 930-2011), and it conforms with the ethical guidelines of the 1975 Declaration of Helsinki. All patients gave written informed consent to participate in this study. Healthy volunteers were also recruited from Hannover Medical School.
Sample Collection and Cell Isolation
Blood was obtained during the medical examination and was processed on the same day. Peripheral blood mononuclear cells were isolated with a Ficoll density gradient. Peripheral blood mononuclear cells were resuspended in a freezing medium (15-20 3 10 6 /mL) containing 60% fetal bovine serum, 10% dimethyl sulfoxide, and an aliquot in cryotubes. Cryotubes were stored in liquid nitrogen until further analysis.
Flow Cytometry Staining of Tregs
Frozen peripheral blood mononuclear cells were thawed and stained with a master mix of the different antibodies (Table 4) for 15 minute at 4 C in the dark. Afterwards, the wells were washed twice and resuspended in a fluorescence-activated cell sorting (FACS) buffer. For FoxP3 staining, a human FoxP3 staining kit (BD Pharmingen, Franklin Lakes, NJ) was used Fig. 1A .
Antibodies
The following fluorochrome-conjugated monoclonal antibodies were used for flow cytometry (clones): anti-CD4 APC-H7 (RPA-T4), anti-CD25 PE and PE-Cy7 (M-A251), anti-CD45RA V450 (HI100), anti-CD49d PECy5 (9F10), anti-CD62L FITC (DREG-56), anti-CD127 AF647 and PerCP-Cy5.5 (hIL-7R-M21), anti-CTLA-4 PE and APC (BNI3), anti-FoxP3 PE and AF647 (259D/ C7), anti-HLA-DR FITC (TU36), anti-ICOS FITC (ISA-3), LAP-TGFb APC (27232). Additionally, the following biotin-conjugated monoclonal antibodies were used: anti-CD39 biotin (A1) and anti-chemokine (C-C motif) receptor 7 (anti-CCR7) biotin (3D12). They were conjugated with SA Texas Red and SA AF405.
Statistical Analysis
The statistical analysis was performed with Prism for Macintosh (GraphPad, San Diego, CA). Data sets were tested for normal distributions with the D'Agostino and Pearson omnibus test or with the Shapiro-Wilk test when the sample size was smaller than 20.
The homogeneity of variances (homoscedasticity) was analyzed with the F test or the Bartlett test. A t test and an analysis of variance were used whenever parametrical testing applied (normal distribution and homoscedasticity), and the Mann-Whitney test and the Kruskal-Wallis test were used when the data set had to be analyzed with a nonparametric test. P 0.05 was considered significant. Statistically significant differences are marked as follows: *P 0.05, **P < 0.01, and ***P < 0.001.
A principal component analysis (PCA) of the clinical and experimental parameters of this study was conducted with Qlucore Omics Explorer 2.3 software (Qlucore AB, Lund, Sweden).
PCA is a well-established method that transforms a large set of parameters into 3 summary variables (main components), which are illustrated as 3 axes. PCA visualizes multidimensional data because it creates a 3-dimensional image that can instantly be 
FoxP3
1 was correlated for 2 different fluorochromes. When the data followed a normal distribution, a Pearson correlation was applied; if not, a Spearman correlation was used. 102, 80, and 80 pairs, respectively, were tested after they were stained for the combinations listed in Table  4 .
interpreted in terms of interrelationships among samples. It helps to identify parameters that differentiate sample groups or to categorize new groups of samples that share 1 or more characteristics.
In order to compare parameters with different ranges of values, results were log 2 -converted, and the variance was normalized to 1. Missing values were imputed with k-nearest neighbors. Thresholds of 0.05 for P and 0.2 for the false discovery rate (q) were applied throughout the study.
RESULTS
Tregs were extensively phenotypically characterized in order to better define their role and function in the context of LT, with a particular focus on patients infected with HCV. Three separate staining panels with 4 parameters defining Tregs (CD4, CD25 hi , CD127 -, and FoxP3) were applied for each sample in addition to HLA-DR, CCR7, CD45RA, CD62L, CD49d, CD39, ICOS, and LAP-TGFb staining ( Fig. 1A and Supporting Fig. 1 ). The different staining panels are described in Table 4 . For this study, Tregs were defined as
1 as previously described by Liu et al. 7 The strong correlation between CD127 -and FoxP3 1 was also confirmed for LT recipients, as shown in Fig. 1B . The combination of 3 different panels enabled a very robust characterization of the samples and allowed high quality control.
To further characterize Tregs and their subpopulations, groups were defined on the basis of the surface markers CD45RA and CCR7, 32 and naive Tregs were additionally described as CD45RA 1 CD62L 1 . 33 HLA-DR 1 Tregs have been previously described as a functionally distinct population with a high suppressive effect that might play a role in organ rejection. [34] [35] [36] Additionally, earlier publications have shown that CD49d -Tregs are free of contaminating activated T cells and result in purer populations of FoxP3 1 Tregs. 37 The overall frequency of Tregs (regardless of the panel used for their definition) remained stable over time after transplantation, as shown in Supporting Fig. 3 . This holds true also for their further characterization (depending on CD45RA and CCR7), with the exception of naive Tregs, which were slightly more frequent in the first 6 months after transplantation in comparison with later time points (Supporting Fig. 4) . The percentage of HLA-DR 1 Tregs showed a slight increase over time, but CD49d -Tregs remained stable (Supporting Fig. 5 ).
Similar Frequencies of Tregs in LT Patients and Healthy Subjects
We first compared Tregs from LT patients and healthy controls. Peripheral blood mononuclear cells from LT patients and healthy donors showed no differences in their Treg frequencies. The 2 groups had similar mean frequencies for CD127 -and FoxP3 1 Tregs (Fig. 2A,B) . LT patients and healthy donors presented with similar distributions and frequencies of Treg subpopulations (Fig. 2C) . No differences in naive CD45RA
Tregs were observed between LT patients and healthy controls (Fig. 2D) . When the percentages of HLA-DR 1 Tregs in the LT patients and the healthy individuals were compared, again, no difference was observed (Fig.  2E) . LT patients showed a lower frequency of CD49d -Tregs in comparison with healthy donors (Fig. 2F) .
Overall, Tregs showed similar frequencies and phenotypes in patients who had undergone LT and healthy subjects, although there were some differences in the subpopulations. This suggests a lack of major disturbances of Treg populations in LT recipients.
Higher Effector Memory Tregs in HCV LT Patients Versus Non-HCV LT Patients
The next aim of this study was to compare HCV LT patients to LT recipients without recurrence of the initially underlying liver disease (non-HCV LT patients) in order to identify possible differences due to the active HCV infection. Tregs were found in HCV LT patients versus non-HCV LT patients (Fig. 3A,B) . Treg subpopulations in HCV LT patients showed lower percentages for naivelike Tregs gated as CD45RA 1 CCR7
1 but not as CD45RA 1 CD62L 1 (Fig. 3C,D) . HCV LT patient samples also had fewer Tregs with a memory phenotype (defined as CD45RA -CCR7
1
) in comparison with samples from non-HCV LT patients (P 5 0.09). Tregs that showed an effector phenotype (CD45RA   -CCR7 -) were present at a higher percentage in the HCV LT patients. No differences could be found when the percentages of HLA-DR 1 Tregs or CD49d -Tregs were compared in HCV LT patients and non-HCV LT patients (Fig. 3E,F) . In summary, no difference in the overall frequency of Tregs could be observed between LT patients with a persistent HCV infection and those without one. Nevertheless, distinct subpopulations of Tregs showed different distributions in the 2 groups: although naive and memory phenotypes were found at lower frequencies in the HCV LT patients, these showed a significantly increased frequency of Tregs with a CD45RA -CCR7 -effector phenotype.
Treg Phenotypes Differed Between Chronic HCV Patients and HCV-Infected Patients After LT
Because Tregs from HCV LT patients showed different phenotypes, we next aimed to investigate whether they would differ from those in HCV-infected individuals (HCV CHR patients). Treg frequencies based on the CD4 1 CD25 hi CD127 -definition were significantly lower in HCV LT patient samples versus samples from chronic HCV patients (Fig. 4A) . This difference could no longer be observed when the frequencies of CD4 (Fig. 4E) . In line with the findings for Treg frequencies (Fig. 4A) , LT HCV patients had lower percentages of CD49d -Tregs in comparison with nontransplant chronic HCV patients (Fig. 4F) 
Different Distributions of Functional Parameters on Tregs in Samples From Healthy Patients, HCV LT Patients, Non-HCV LT Patients, and HCV CHR Patients
Tregs assert their suppressive capacity through different mechanisms. In this study, CD39, ICOS, and LAP-TGFb were analyzed and quantified with flow cytometry. It has been shown that ICOS, LAP-TGFb, and CD39
38-40 play a vital role in mediating the suppressive function of Tregs. These markers on their own did not possess a high resolution power for differentiating between the patient groups studied here. Figure 5 shows the frequency of Tregs that were positive for CD39 (Fig. 5A), ICOS (Fig. 5B) , and LAP-TGFb (Fig. 5C ) in the 4 analyzed groups (healthy individuals, HCV LT patients, non-HCV LT patients, and nontransplant chronic HCV patients). No difference or pattern could be observed.
A multiparameter analysis was performed; single positive subsets were grouped with a Boolean analysis. The groups were ranked according to the number of functional parameters (CD39, ICOS, and LAPTGFb) present on their Tregs (Fig. 5D ). This classification revealed that most of the Tregs of healthy donors expressed no functional markers (64%) or only 1 functional marker (27%). Similarly, 78% of all Tregs from non-HCV LT patients were positive for none of the tested functional markers. In contrast, HCV LT patients had a higher percentage of Tregs positive for 1 or more of the functional parameters. HCV LT patients and chronic HCV patients showed very similar expression patterns of functional markers on Tregs. In both groups, most of the Tregs were positive for 1 or 2 functional markers. Thus, this multiparameter analysis as a surrogate of functionality (ICOS, LAP-TGFb, and CD39) revealed similarities between the HCV LT patients and the nontransplant chronic HCV group with respect to the distribution of functional markers on Tregs. To the same extent, Tregs from healthy individuals and non-HCV LT patients showed functional similarities. As a result, these data might suggest that HCV infection, but not transplantation, is associated with multifunctional Tregs.
PCA of Treg Markers Distinguished Different Patient Cohorts
In order to further validate the results and explore relationships among samples and patient groups, PCA was performed with the various Treg subpopulations and surface markers studied here. Each point on a PCA plot represents a blood sample, and its position with respect to the axis is determined by the combined effects of all parameters measured for that sample. The distance between sample points represents the Euclidean distance. The main 3 component vectors are displayed as axes, and the percentage signifies the proportion of the variability in the data for which each component accounts.
Notably, PCA did not identify any statistically significant parameters with an acceptable q value that could differentiate LT patients from healthy individuals (Fig. 6A) .
In contrast, HCV LT patients and non-HCV LT patients showed partial clustering on a PCA plot (Fig.  6B) 
Treg Phenotypes Differentiated Graft Rejection From Graft HCV in LT Patients
We finally asked whether Treg phenotypes could differentiate patients suffering from graft rejection from transplant recipients with histologically confirmed recurrent HCV. The 2 patient subgroups did not differ in key characteristics, including age, sex, time after transplantation, HCV genotype, and immunosuppression (data not shown). As shown in a PCA plot (Fig. 7A) , Treg phenotypes of HCV LT patients with acute rejection clustered together and could be clearly separated from Tregs derived from individuals with graft HCV. HCV-infected patients with rejection were not differentiated in the PCA from HCVnegative patients with rejection (data not shown). The parameters that differed between the 2 groups were CD62L
1
CD45RA
1 Tregs, HLA-DR 1 Tregs, and 
CD39
-ICOS 1 LAP-TGFb -Tregs. Individual differences in these markers were confirmed with an unpaired t test or the Mann-Whitney test, as shown in Fig. 7B -D. The percentage of HLA-DR 1 Tregs was reduced in HCV LT patients suffering rejection versus those with graft HCV (Fig. 7B) . This difference was independent of the time of the investigation after transplantation (before and after 6 months after transplantation; data not shown). On the contrary, the percentage of CD62L 1 CD45RA
1
Tregs was increased in HCV LT patients with rejection versus patients with graft HCV (Fig. 7C) . HCV LT patients with liver rejection had a higher number of naivelike Tregs. The difference in CD39 -ICOS 1 LAP-TGFb -Tregs between the 2 patient groups was not statistically significant (Fig. 7D) . 
DISCUSSION
This study represents, to our knowledge, the largest and broadest phenotypic analysis of Tregs in LT recipients so far. Tregs were analyzed in 3 independent staining panels with different markers, which allowed stringent quality control. We, therefore, believe that the presented data set is very robust with limited confounding factors. The first-and not trivial-finding from this data set is that FoxP3 and CD127 expression shows a strong negative correlation also in cells derived from organ transplant recipients receiving various medications. When we consider potential therapeutic strategies for isolating Tregs from these patients, 41 surface CD127 expression seems to be a reliable marker that can be included also in sorting strategies for purifying Tregs in patients treated with immunosuppressive drugs.
Several key findings have come from this study. We have shown that (1) the overall frequencies of Tregs and Treg subpopulations do not differ between LT recipients and healthy individuals, (2) Tregs with a CD45RA -CCR7 -effector phenotype are enriched in the peripheral blood of LT recipients with chronic HCV versus HCV-negative transplant patients, (3) HCV infection, rather than LT, alters the expression -ICOS 1 LAP-TGFb -Tregs between the 2 patient groups was not statistically significant. Statistically significant differences are marked by * P < 0.05, ** P < 0.01. levels of functional markers on Tregs, and (4) Treg phenotypes (particularly HLA-DR and markers indicating naivelike cells) may differentiate HCV-infected LT recipients with rejection from patients with recurrent graft HCV.
Previous studies reported reduced Treg frequencies in the blood of patients after transplantation versus healthy controls, 42, 43 and this contrasts with the findings presented here, which show similar overall Treg frequencies in the 2 populations. We also need to acknowledge that calcineurin inhibitors have been shown to decrease the frequency of Tregs. 44 Individual treatments and even the differences between cyclosporine A and tacrolimus probably would need to be taken into account to pinpoint changes. Overall, the immunosuppressive regimen did not show a demonstrable effect in the bulk of the LT patients analyzed. Even though minor differences were also found in our study for some Treg subpopulations (eg, CD4
1 CD25 hi FoxP3 1 CD49d -), the data do not indicate major general alterations of the Treg pool in LT recipients. Still, changes over time may occur.
Indeed, a study from Rotterdam reported initial declines of Treg populations after LT, particularly during rejection episodes, with subsequent reincreases until month 12 after transplantation. 45 This could suggest that a Treg homeostasis might establish itself only some time after transplantation. In the present cross-sectional data set, Treg frequencies did not differ in samples obtained during the first 6 months after transplantation and samples obtained later. It is striking that LT recipients and healthy individuals showed not only rather similar Treg frequencies but also no major alterations in Treg functional markers. This further supports the conclusion that despite ongoing immunosuppression, Tregs do not suffer general disturbances after LT, and the Treg population adjusts itself within the network of immune responses. This is also supported by the observation that neither the frequency of Tregs nor the phenotype of Tregs after LT was related to any pathological correlates of liver damage or viral loads.
Even if the Treg frequency and phenotype seemed to be rather robust in the LT recipients, distinct profiles were observed between HCV LT patients and non-HCV LT patients. Naive and memory phenotype Tregs were reduced, whereas Tregs with a CD45RA -CCR7 -effector phenotype were more frequent in HCV LT patients. Moreover, a broader repertoire of functional parameters was observed on Tregs from HCV-infected LT recipients and on cells derived from nontransplant control individuals with chronic HCV. Collectively, these findings may indicate that the ongoing viral infection triggers antiviral immune responses, which force the Treg population to engage in higher functionality and effectorlike phenotypes. 37 However, their suppressive capacity is still under debate, with some results showing a lower capacity 38 and others showing a highly suppressive capacity in vitro. 48 Distinct profiles of CD45RA, CCR7, and CD62L have been linked to differences in Treg functionality. For example, Tregs expressing a naive phenotype are highly suppressive. 49, 50 Subsequently, a protective effect of CD45RA
1
CD62L
1 Tregs in avoiding rejection has been suggested in patients after stem cell transplantation. 33 In this context, it is interesting that Tregs from transplant patients with chronic HCV were more likely to have an effector CD45RA -CCR7 -phenotype. Future studies need to investigate whether these cells are also less functional than naivelike Tregs in the context of HCV and whether this shift in Treg populations may make HCV-infected patients more susceptible to rejection episodes. 51 Moreover, it would be interesting if functionally reduced Treg subpopulations are a characteristic feature of HCV infection after LT or if other persistent infections lead to similar disturbances of the Treg pool.
A major clinical challenge in the management of posttransplant HCV is the differentiation between rejection and HCV-induced graft hepatitis because the 2 conditions lead to basically opposite treatment decisions. 4 Following the aforementioned alterations of the Treg phenotype and function in HCV-infected LT patients, we wondered whether the 2 clinical conditions lead to particular changes in Treg profiles. To address this question, an unbiased approach was applied with a PCA that included all parameters determined for Tregs. Strikingly, patients with histologically proven rejection could clearly be separated from individuals with HCV-associated graft injury on the basis of Treg phenotypes in the PCA. HCVinfected patients with rejection were not differentiated in the PCA from HCV-negative patients with rejection (data not shown). Markers potentially associated with higher immunosuppressive function, such as a naivelike phenotype or the expression of CD39, ICOS, and LAP-TGFb, were not lower but instead were higher in patients with rejection. This is well in line with a previous finding by some of us demonstrating higher frequencies of Foxp3 1 Tregs in grafts of patients with higher rejection activity indices. 27 These findings could indicate that changes in Treg frequencies and function are a response to an increased alloimmune response rather than the cause of rejection. However, individual parameters may be of limited clinical diagnostic value because a reliable separation of the 2 groups was possible only with combined PCA.
Even though several aims were achieved in this work, the study has obvious limitations that need to be acknowledged. Although the overall number of investigated samples was extensive, the numbers for the subgroups (especially transplant recipients with HCV) were still limited. In addition, the amount of cells obtained from patients receiving immunosuppressive medications was limited, and because of this, no functional assays could be performed. However, functional experiments are needed to also prove functional alterations of Tregs in HCV-infected LT recipients, even though the value of the functional surrogate markers investigated here is well established. These experiments would also include a broader analysis of the Treg cytokine profile. Furthermore, only peripheral blood was tested because the number of cells obtained from liver biopsies was too small to apply large flow cytometry-based phenotyping panels. To understand better the role of Tregs over time after transplantation, a longitudinal analysis should follow our cross-sectional approach, and a parallel investigation of HCV-specific effector immune responses would be of major interest. Finally, the effects of antiviral therapy on Tregs remain to be investigated. Novel interferon-free treatment approaches are reaching the market, and thus a large proportion of patients could be cured during the next years. [52] [53] [54] It will be very interesting to see whether the HCV imprint on the Treg phenotype and function can be reversed by these therapies.
In summary, Treg phenotypes but not Treg frequencies may differentiate HCV-infected patients after LT. An investigation of Tregs could help us to distinguish the clinically challenging differential diagnosis of recurrent HCV from graft rejection and to better understand the immunopathophysiology of HCV infection after LT. 
